000304469 001__ 304469
000304469 005__ 20250909114905.0
000304469 0247_ $$2doi$$a10.1158/1535-7163.MCT-25-0428
000304469 0247_ $$2pmid$$apmid:40911901
000304469 0247_ $$2ISSN$$a1535-7163
000304469 0247_ $$2ISSN$$a1538-8514
000304469 037__ $$aDKFZ-2025-01862
000304469 041__ $$aEnglish
000304469 082__ $$a570
000304469 1001_ $$00000-0002-8356-5191$$aDela Cruz, Filemon S$$b0
000304469 245__ $$aAdvancing preclinical biology for Ewing Sarcoma: an international effort.
000304469 260__ $$aPhiladelphia, Pa.$$bAACR$$c2025
000304469 3367_ $$2DRIVER$$aarticle
000304469 3367_ $$2DataCite$$aOutput Types/Journal article
000304469 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1757409319_22247
000304469 3367_ $$2BibTeX$$aARTICLE
000304469 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000304469 3367_ $$00$$2EndNote$$aJournal Article
000304469 500__ $$aepub
000304469 520__ $$aEwing sarcoma (EwS) is an aggressive bone and soft tissue cancer affecting adolescents and young adults. In vitro and in vivo models of EwS have been instrumental in advancing our understanding of EwS biology and essential in evaluating potential therapies, particularly for metastatic or relapsed disease where effective treatment options remain limited. Through an international collaborative effort between the Children's Oncology Group (COG) Bone Tumor Committee and the Euro Ewing Consortium (EEC), we review the current landscape of preclinical modeling used in EwS research encompassing both in vitro (cell lines and tumor organoids) and in vivo (mouse and non-mammalian xenografts) model systems. We discuss factors that can influence experimental results, provide testing considerations for both in vitro and in vivo studies, and descriptions of existing preclinical data repositories. We highlight current needs in EwS modeling and the importance of enhanced international cooperative research and patient advocacy efforts which will be critical in expanding our resources of biologically-relevant EwS models to enable translation of preclinical findings into effective therapeutic strategies for EwS patients.
000304469 536__ $$0G:(DE-HGF)POF4-312$$a312 - Funktionelle und strukturelle Genomforschung (POF4-312)$$cPOF4-312$$fPOF IV$$x0
000304469 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000304469 7001_ $$00000-0001-8005-0427$$aStewart, Elizabeth A$$b1
000304469 7001_ $$00000-0002-7118-7859$$aSurdez, Didier$$b2
000304469 7001_ $$00000-0001-5133-448X$$aDaley, Jessica D$$b3
000304469 7001_ $$00000-0002-6634-2885$$aSoragni, Alice$$b4
000304469 7001_ $$00000-0002-7497-4567$$aTomazou, Eleni M$$b5
000304469 7001_ $$00009-0007-4897-5121$$aAlvarez-Perez, Jaime$$b6
000304469 7001_ $$00000-0003-2897-036X$$aFeinberg, Tamar Y$$b7
000304469 7001_ $$00000-0002-9901-2137$$aAmatruda, James F$$b8
000304469 7001_ $$00000-0002-1239-2166$$aGanapathi, Shireen S$$b9
000304469 7001_ $$00000-0002-7390-8701$$aOhm, Joyce E$$b10
000304469 7001_ $$00000-0003-0956-6249$$aHeske, Christine M$$b11
000304469 7001_ $$00000-0002-8852-1104$$aCohen-Gogo, Sarah$$b12
000304469 7001_ $$00009-0007-4201-0257$$aPesic, Dusan$$b13
000304469 7001_ $$00009-0003-2718-2262$$aNash, Joshua O$$b14
000304469 7001_ $$00000-0002-0368-5370$$aShlien, Adam$$b15
000304469 7001_ $$00000-0002-0508-3648$$aRoundhill, Elizabeth A$$b16
000304469 7001_ $$00000-0002-1034-3723$$aBurchill, Susan A$$b17
000304469 7001_ $$00000-0001-9404-6621$$aCrompton, Brian D$$b18
000304469 7001_ $$00000-0002-2350-1540$$aLawlor, Elizabeth R$$b19
000304469 7001_ $$00000-0002-7319-5000$$aLoeb, David M$$b20
000304469 7001_ $$00000-0002-8730-2276$$aDelattre, Olivier$$b21
000304469 7001_ $$00000-0002-9386-5980$$aMora, Jaume$$b22
000304469 7001_ $$00000-0001-6114-9499$$aScotlandi, Katia$$b23
000304469 7001_ $$00000-0002-8238-2465$$aReed, Damon R$$b24
000304469 7001_ $$00000-0002-1071-4563$$aGrohar, Patrick J$$b25
000304469 7001_ $$0P:(DE-He78)7a590ab95c6f7ba52880452da78ecd6c$$aGrünewald, Thomas$$b26$$udkfz
000304469 7001_ $$00000-0001-6873-9109$$aKovar, Heinrich$$b27
000304469 7001_ $$00000-0003-3925-3243$$aBailey, Kelly M$$b28
000304469 773__ $$0PERI:(DE-600)2062135-8$$a10.1158/1535-7163.MCT-25-0428$$pnn$$tMolecular cancer therapeutics$$vnn$$x1535-7163$$y2025
000304469 909CO $$ooai:inrepo02.dkfz.de:304469$$pVDB
000304469 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)7a590ab95c6f7ba52880452da78ecd6c$$aDeutsches Krebsforschungszentrum$$b26$$kDKFZ
000304469 9131_ $$0G:(DE-HGF)POF4-312$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vFunktionelle und strukturelle Genomforschung$$x0
000304469 9141_ $$y2025
000304469 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2024-12-19
000304469 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2024-12-19
000304469 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2024-12-19
000304469 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2024-12-19
000304469 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2024-12-19
000304469 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2024-12-19
000304469 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2024-12-19
000304469 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2024-12-19
000304469 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2024-12-19
000304469 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bMOL CANCER THER : 2022$$d2024-12-19
000304469 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bMOL CANCER THER : 2022$$d2024-12-19
000304469 9201_ $$0I:(DE-He78)B410-20160331$$kB410$$lTranslationale Pädiatrische Sarkomforschung$$x0
000304469 9201_ $$0I:(DE-He78)HD01-20160331$$kHD01$$lDKTK HD zentral$$x1
000304469 980__ $$ajournal
000304469 980__ $$aVDB
000304469 980__ $$aI:(DE-He78)B410-20160331
000304469 980__ $$aI:(DE-He78)HD01-20160331
000304469 980__ $$aUNRESTRICTED